Hubei Biocause Heilen Pharmaceutical Co. Ltd. Cash Flow Conversion Efficiency

Latest as of September 2025: 0.005x

Hubei Biocause Heilen Pharmaceutical Co. Ltd. cash flow conversion efficiency. Based on the latest financial reports, Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥11.57 Million ≈ $1.69 Million USD) by net assets (CN¥2.26 Billion ≈ $330.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)

Cash flow conversion efficiency of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2025. This chart illustrates how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View 301211 stock price for real-time trading data and today's change.

Hubei Biocause Heilen Pharmaceutical Co. Ltd. Cash Flow Conversion Ratio Explained

Hubei Biocause Heilen Pharmaceutical Co. Ltd. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Hubei Biocause Heilen Pharmaceutical Co. Ltd. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hubei Biocause Heilen Pharmaceutical Co. Ltd. ranked by their cash flow conversion efficiency. Also see 301211 company net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Sinovac Biotech Ltd NASDAQ:SVA	0.023x
BFI Finance Indonesia Tbk JK:BFIN	0.064x
Marimaca Copper Corp TO:MARI	-0.071x
New Mountain Finance Corporation NASDAQ:NMFC	0.024x
Shenzhen Grandland Decoration Group Co Ltd SHE:002482	0.133x
Platzer Fastigheter Holding AB (publ) ST:PLAZ-B	0.016x
New York Mortgage Trust Inc NASDAQ:NYMT	0.028x
Basellandschaftliche Kantonalbank SW:BLKB	-0.313x

Annual Cash Flow Conversion Efficiency for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)

The table below shows the annual cash flow conversion efficiency of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2025. Review Hubei Biocause Heilen Pharmaceutical Co. free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥2.27 Billion ≈ $332.64 Million	CN¥7.55 Million ≈ $1.10 Million	0.003x	-92.01%
2024-12-31	CN¥2.31 Billion ≈ $337.98 Million	CN¥96.07 Million ≈ $14.06 Million	0.042x	-28.48%
2023-12-31	CN¥2.36 Billion ≈ $344.86 Million	CN¥137.06 Million ≈ $20.06 Million	0.058x	-47.21%
2022-12-31	CN¥2.28 Billion ≈ $333.12 Million	CN¥250.79 Million ≈ $36.70 Million	0.110x	+97.51%
2021-12-31	CN¥2.22 Billion ≈ $325.26 Million	CN¥123.98 Million ≈ $18.14 Million	0.056x	-67.89%
2020-12-31	CN¥700.39 Million ≈ $102.49 Million	CN¥121.67 Million ≈ $17.80 Million	0.174x	-77.22%
2019-12-31	CN¥488.25 Million ≈ $71.45 Million	CN¥372.33 Million ≈ $54.48 Million	0.763x	+300.27%
2018-12-31	CN¥399.87 Million ≈ $58.51 Million	CN¥76.18 Million ≈ $11.15 Million	0.191x	+189.57%
2017-12-31	CN¥307.65 Million ≈ $45.02 Million	CN¥-65.44 Million ≈ $-9.58 Million	-0.213x	--

About Hubei Biocause Heilen Pharmaceutical Co. Ltd.

SHE:301211 China Drug Manufacturers - Specialty & Generic

Market Cap

$642.25 Million

CN¥4.39 Billion CNY

Market Cap Rank

#10623 Global

#2815 in China

Share Price

CN¥10.51

Change (1 day)

-0.28%

52-Week Range

CN¥9.28 - CN¥16.03

All Time High

CN¥44.40